Investigator Assessment of the Utility of the TruGraf Molecular Diagnostic Test in Clinical Practice

TruGraf v1 is a well-validated DNA microarray-based test that analyzes blood gene expression profiles as an indicator of immune status in kidney transplant recipients with stable renal function. In this study, investigators assessed clinical utility of the TruGraf test in patient management. In a re...

Full description

Saved in:
Bibliographic Details
Published in:Transplantation proceedings 2019-04, Vol.51 (3), p.729-733
Main Authors: First, M.R., Peddi, V.R., Mannon, R., Knight, R., Marsh, C.L., Kurian, S.M., Rice, J.C., Maluf, D., Mandelbrot, D., Patel, A., David, J., Schieve, C., Lee, D., Lewis, P., Friedewald, J.J., Abecassis, M.M., Rose, S.
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:TruGraf v1 is a well-validated DNA microarray-based test that analyzes blood gene expression profiles as an indicator of immune status in kidney transplant recipients with stable renal function. In this study, investigators assessed clinical utility of the TruGraf test in patient management. In a retrospective study, simultaneous blood tests and clinical assessments were performed in 192 patients at 7 transplant centers, and in a prospective observational study they were performed in 45 subjects at 5 transplant centers. When queried regarding whether or not the TruGraf test result impacted their decision regarding patient management, in 168 of 192 (87.5%) cases the investigator responded affirmatively. The prospective study indicated that TruGraf results supported physicians' decisions on patient management 87% (39/45) of the time, and in 93% of cases physicians indicated that they would use serial TruGraf testing in future patient management. A total of 21 of 39 (54%) reported results confirmed their decision that no intervention was needed, and 17 of 39 (44%) reported that results specifically informed them that a decision not to perform a surveillance biopsy was correct. TruGraf is the first and only noninvasive test to be evaluated for clinical utility in determining rejection status of patients with stable renal function and shows promise of providing support for clinical decisions to avoid unnecessary surveillance biopsies with a high degree of confidence. TruGraf is an invaluable addition to the transplant physician's tool kit for managing patient health by avoiding painful and invasive biopsies, reducing health care costs, and enabling frequent assessment of patients with stable renal function to confirm immune quiescence. •TruGraf is a well-validated DNA microarray-based test that analyzes blood gene expression profiles as an indicator of immune status in kidney transplant recipients with stable renal function.•In both a retrospective and prospective clinical study the clinical utility of the TruGraf test was demonstrated.•TruGraf is the first and only noninvasive test to be evaluated for clinical utility in determining rejection status of patients with stable renal function and has the potential to support clinical decisions to avoid unnecessary surveillance biopsies with high confidence.
ISSN:0041-1345
1873-2623
DOI:10.1016/j.transproceed.2018.10.024